From: The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis
Nafmostat mesilate (n = 201) | Control (n = 149) | Total (N = 350) | P value | |
---|---|---|---|---|
Age, y, median (range) | 68 (55–75) | 66 (54–74) | 66 (55–75) | 0.436 |
Male (%) | 74 (36.8) | 59 (39.6) | 133 (38.0%) | 0.596 |
History of AP (%) | 3 (1.5) | 0 | 3 (0.9%) | |
SOD (%) | 2 (1.0) | 0 | 2 (0.6%) | |
Purpose of ERCP (%) | ||||
Choledocholithiasis | 120 (59.7) | 81 (54.4) | 201 (57.4%) | 0.318 |
Malignant biliary stricture | 67 (33.3) | 56 (37.6) | 123 (35.1%) | 0.410 |
Benign biliary stricture | 11 (5.5) | 8 (5.4) | 19 (5.4%) | 0.966 |
Biliary leakage | 0 | 1 (0.7) | 1 (0.3%) | |
Pancreatic cyst | 1 (0.5) | 2 (1.3) | 3 (0.9%) | 0.577 |
Other indicationa | 2 (1.0)* | 1 (0.7) | 3 (0.9%) | 0.745 |
Procedures (%) | ||||
Difficult cannulation | 115 (57.2) | 59 (39.6) | 174 (49.7%) | 0.001 |
P-duct manipulation | 69 (34.3) | 44 (29.5) | 113 (32.3%) | 0.342 |
Precut EST | 70 (34.8) | 42 (28.2) | 112 (32.0%) | 0.188 |
Pancreatic EST | 44 (21.9) | 20 (13.4) | 64 (18.3%) | 0.043 |
EPBD | 21 (10.4%) | 18 (12.1%) | 39 (11.1%) | 0.631 |
ERPD | 43 (21.4%) | 20 (13.4%) | 63 (18.0%) | 0.055 |